Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II Safety Study of ZD4054 10 mg in Metastatic Castration-resistant Prostate Cancer After Chemotherapy
2009-013232-20Phase 2Terminated
- Sponsor
- Aarhus University Hospital, Department of Urology
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zibotentan in prostate cancer (PCa), sponsored by Aarhus University Hospital, Department of Urology. Primary endpoints: Safety and tolerability of ZD4054 10 mg once daily and Effect on rate of rise of PSA. Started Jul 2009; status: terminated.
02
Drugs
zibotentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-013232-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013232-20.